Abstract
BackgroundThe UK MHRA has introduced a risk-proportionate approach to the approval and management of clinical trials of investigational medicinal products (CTIMP). The aim is to reduce the complexity of regulations...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have